The medical polymers market valued at USD 22.1 billion in 2025, is project to reach USD 23.5 billion in 2026 and USD 46.0 billion by 2035, representing a higher CAGR of 7.7% during the forecast period 2026 to 2035. In terms of type of polymer, the thermoplastic polymers segment holds the highest share of the market. With regards to area of application, the medical devices segment dominates the global market. Based on geographical regions, North America captures the majority of the market sha...

The global blood brain barrier market, valued at USD 38 million in 2025, is projected to reach USD 252 million in 2026 and USD 2,904 million by 2035, with a 31.2% CAGR during the forecast period 2026 to 2035. Neurological disorders are the second highest cause of death and the leading cause of disability, worldwide. In 2021, it was reported that nearly 3.4 billion global population suffer from some form of disorder that affects the functioning of the CNS. More than 6 million people are reported...

The global smart labels market, valued at USD 5.4 billion in 2025, is projected to reach USD 6.4 billion in 2026 and USD 24.0 billion by 2035, with a 16% CAGR during the forecast period 2026 to 2035. In terms of type of technology, the RFID segment holds the highest share (75%) of the market. With regards to type of packaging, the primary packaging segment dominates the global market with 95% market share. Based on the type of primary packaging, the syringes reagents hold the largest market shar...

With over 60 known use-cases wherein pharma companies have actively deployed green chemistry in their research / manufacturing process, the green chemistry market is expected to steadily evolve. It is worth highlighting that up to 75% of the pharmaceutical pipeline is anticipated to benefit from biocatalytic methods. The photochemistry of majority of these green approaches offer improvement in yield and reduction in waste, optimizing manufacturing time as well as solvent use

The dermal fillers market valued at USD 3.33 billion in 2024, is project to reach USD 3.64 billion in 2025 and USD 8.81 billion by 2035, representing a higher CAGR of 9.25% during the forecast period 2025 to 2035. Amongst the end users, the hospitals segment dominates the global market.  Based on the distribution channel, direct distribution channel segment holds the largest market share (nearly 80%. In terms of geography, North America captures majority of the market share (close to 50%).

The cell line development market size valued at USD 1.46 billion in 2025, is project to reach USD 1.69 billion in 2026 and USD 4.50 billion by 2035, representing a higher CAGR of 11.5% during the forecast period 2026 to 2035. In terms of source of cell line, mammalian cells segment dominates the market with a 74% revenue share due to their critical role in producing complex proteins, monoclonal antibodies, and cell- and gene-based therapies. Notably, mid-sized players lead the market with a 39%...

Owing to the rising space exploration, and requirement of medicine, space medicine demand is likely to increase in the upcoming years. The emerging needs has catered the attention of pharmaceutical industries to undertake several initiatives to strengthen the development of space medicine. However, the primary focus will be on telemedicine, remote monitoring / surgery technologies, and virtual consultation to provide quick support to astronauts to improve overall well-being.Additionally, several...

The global virtual clinical trials market, valued at $12.9 billion in 2025, is projected to reach $13.6 billion in 2026 and $30.5 billion by 2035, representing a CAGR of 9.4% during the forecast period 2026 to 2035. In terms of type of study, the interventional segment holds the highest share (75%) of the market. With regards to mode of virtual clinical trials, the hybrid clinical trials segment dominates the global market. Based on the therapeutic area, the oncological disorders segment holds t...

The global taste masking services market, valued at USD 260 million in 2025, is projected to reach USD 276 million in 2026 and USD 476 million by 2035, with a 6.3% CAGR during the forecast period 2026 to 2035. Even though the demand for biologics is increasing rapidly, the oral solid dosage captures the largest share in the pharmaceutical industry, estimated to reach more than USD 900 billion by 2027. However, one of the major concerns is that orally administered dosage forms have active pharmac...

With increasing demand, several market players, such as Medtronic (US), and Abbott Laboratories (US) are undertaking initiatives to develop minimally invasive surgery solutions. For instance, in October 2025, Medtronic announced the initiation of the embrace gynecology investigational device exemption (IDE) US clinical study to evaluate the effectiveness and safety of its Hugo™ robotic-assisted surgery (RAS) system in robotic-assisted gynecological procedures. As more market players focus on t...

The global nutrigenomics market, valued at USD 0.92 billion in 2025, is projected to reach USD 1.04 billion in 2026 and USD 3.07 billion by 2035, with a 12.8% CAGR during the forecast period 2026 to 2035. It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Nutrigenomics typically refers to the study of the relationship between nutrition, human genomes, and health. Presently, more than...

The global metabolomics market, valued at USD 265 million in 2025, is projected to reach USD 305 million in 2026 and USD 1,059 million by 2035, with a 14.8% CAGR during the forecast period 2026 to 2035. With the growing prominence of personalized medicine, there is an increased demand for rapid, highly sensitive and accurate quantification methods, such as metabolomics, to analyze clinical specimens. In fact, 50% of the total drug candidates are reported to emanate from pre-existing metabolites....

The abuse deterrent formulations market, valued at USD 39.8 billion in 2025, is projected to reach USD 42.5 billion in 2026 and USD 54.8 billion by 2030, with a 6.6% CAGR during the forecast period 2026 to 2030. Although the healthcare industry relies on patient to take medications responsibly, in 2017, close to 18 million individuals were reported to have misused prescription drugs, in the US. Moreover, the same study reported 1.5 million people abusing tranquilizers, over 1 million abusing pr...

RNA therapeutics are known to target specific genetic sequences of individual patients, in order to provide more effective treatment options for a wide range of disorders, with fewer side effects. The development of RNA-based therapeutics initially gained momentum in 2004, with the approval of the first RNA based therapeutic modality, Macugen (developed by Eyetech Pharmaceutics and Pfizer), which was intended for the treatment of neovascular age-related macular degeneration. Since then, owing to...

The global DNA and gene cloning services market, valued at USD 3.12 billion in 2025, is projected to reach USD 3.57 billion in 2026 and USD 14.55 billion by 2035, with a 16.9% CAGR during the forecast period 2026 to 2035. Over time the continuous advancements in genetic engineering and cloning have opened up exciting possibilities for scientists. For instance, gene cloning can help to make therapies for diseases such as cystic fibrosis, cancer, and AIDS. Additionally, gene cloning presents a fa...

The CDK4 / 6 inhibitors market is estimated to grow from USD 11.34 billion in 2024 to reach USD 13.51 billion in 2025 and USD 55.92 billion by 2035, representing a higher CAGR of 15.3% during the forecast period. According to the Breast Cancer Facts and Statistics, in 2025, nearly 3,16,950 women will be diagnosed with invasive breast cancer. According to CDK4 / 6 inhibitors market analysis, currently North America is dominating the market by holding 45% of the overall revenue share.

The global Fc and glycoengineered antibodies market, valued at USD 42.3 billion in 2025, is projected to reach USD 45.7 billion in 2026 and USD 38.7 billion by 2035, during the forecast period 2026 to 2035. Antibody based pharmacological interventions have become one of the fastest growing segments of the biopharmaceutical industry, with over 120 approved monoclonal antibodies, and close to 900 registered trials for clinical evaluation. In fact, it is worth highlighting that, these interven...

The global DNA synthesis market, valued at USD 1.20 billion in 2025, is projected to reach USD 1.46 billion in 2026 and USD 8.63 billion by 2035, with a 22% CAGR during the forecast period 2026 to 2035. It is worth mentioning that a significant driver propelling the global DNA synthesis market is the increasing requirement for synthetic oligonucleotides such as DNA or RNA to develop therapies, including gene therapies, RNA-based therapies, and targeted therapies. Driven by the growing usage of...

The antibiotics market size, valued at USD 37 billion in 2025, is projected to reach USD 37 billion in 2026 and USD 41 billion by 2035, representing a CAGR of 1.2% during the forecast period 2026 to 2035. In terms of type of drug class, the other drug class segment secures >60% of the overall revenue share of the global market. Antibiotics has two types of therapies, such as monotherapies and combination therapies. Of which, monotherapy holds the majority of the share (~80%). With regards to t...

The global gene switch market, valued at USD 795 million in 2025, is projected to reach USD 899 million in 2026 and USD 2,478 billion by 2035, with a 11.93% CAGR during the forecast period 2026 to 2035. Notably, in the past few years, close to 30 cell and gene therapy products have been approved by the US FDA. In addition, over 1,200 cell therapies are currently being evaluated across various clinical stages of development. However, despite various advantages, adverse events are associated with...